These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 32381868)

  • 1. [A Case of Breast Cancer Treated with Adjuvant Chemotherapy in a Patient Receiving Tacrolimus Medication after Liver Transplantation].
    Nakakimura T; Kotake T; Torii M; Lin X; Yoshibayashi H
    Gan To Kagaku Ryoho; 2020 Jan; 47(1):83-85. PubMed ID: 32381868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
    Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
    Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
    Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
    Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of the cellular pharmacodynamics of tacrolimus in living-donor liver transplantation.
    Mijiti A; Matsuno N; Takeuchi H; Unezaki S; Nagao T; Hirano T
    Cell Transplant; 2009; 18(5):657-64. PubMed ID: 19775528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Efficacy and Safety of Tacrolimus in Pakistani Living Donor Liver Transplant Recipients.
    Azam F; Khan M; Bhatti ABH; Dar FS; Ahmad A; Javed N
    J Coll Physicians Surg Pak; 2019 Nov; 29(11):1048-1052. PubMed ID: 31659960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between mRNA expression level of multidrug resistance 1/ABCB1 in blood cells and required level of tacrolimus in pediatric living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Tanaka K; Uemoto S; Inui K
    J Pharmacol Exp Ther; 2008 May; 325(2):610-6. PubMed ID: 18252812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft rejection occurring in post-liver transplant patients receiving cytotoxic chemotherapy: a case series.
    Tan HH; Fiel MI; del Rio Martin J; Schiano TD
    Liver Transpl; 2009 Jun; 15(6):634-9. PubMed ID: 19479807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients.
    Taber DJ; Dupuis RE; Fann AL; Andreoni KA; Gerber DA; Fair JH; Johnson MW; Shrestha R
    Liver Transpl; 2002 Mar; 8(3):219-23. PubMed ID: 11910566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study.
    Trunečka P; Klempnauer J; Bechstein WO; Pirenne J; Bennet W; Zhao A; Isoniemi H; Rostaing L; Settmacher U; Mönch C; Brown M; Undre N; Kazeem G; Tisone G
    Ann Transplant; 2019 Jun; 24():319-327. PubMed ID: 31160549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term use of FK 506 in living related liver transplantation.
    Uemoto S; Tanaka K; Tokunaga Y; Nishizawa T; Sawada H; Katoh H; Yamamoto E; Yamaoka Y; Ozawa K
    Transpl Int; 1994; 7 Suppl 1():S81-4. PubMed ID: 11271341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients.
    Trotter JF; Stolpman N; Wachs M; Bak T; Kugelmas M; Kam I; Everson GT
    Liver Transpl; 2002 Mar; 8(3):212-8. PubMed ID: 11910565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5.
    Hosohata K; Masuda S; Ogura Y; Oike F; Takada Y; Katsura T; Uemoto S; Inui K
    Drug Metab Pharmacokinet; 2008; 23(2):134-8. PubMed ID: 18445994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
    Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
    Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection.
    Viesselmann CW; Descourouez JL; Jorgenson MR; Radke NA; Odorico JS
    Pharmacotherapy; 2016 Mar; 36(3):335-41. PubMed ID: 26877191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of tacrolimus-associated food allergy after liver transplantation.
    Obayashi N; Suzuki M; Yokokura T; Naritaka N; Nakano S; Ohtsuka Y; Sugo H; Kawasaki S; Shimizu T
    Pediatr Int; 2015 Dec; 57(6):1205-7. PubMed ID: 26541649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroids and living liver donation increase tacrolimus blood levels in living donor liver transplantation.
    Charco R; Rimola A; García-Valdecasas JC; Fuster J; Fondevila C; Navasa M; Julian M; Forta V; Brunet M
    Transplant Proc; 2005 Nov; 37(9):3930-1. PubMed ID: 16386588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased sensitivities of peripheral blood mononuclear cells to immunosuppressive drugs in cirrhosis patients awaiting liver transplantation.
    Mijiti A; Matsuno N; Iwahori T; Takeuchi H; Nagao T; Oka K; Hirano T
    Cell Transplant; 2006; 15(10):885-91. PubMed ID: 17299993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower tacrolimus trough levels in the late period after living donor liver transplantation contribute to improvements in long-term clinical outcomes.
    Geng L; Wang LD; Huang JJ; Shen T; Wang ZY; Lin BY; Ye YF; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):204-209. PubMed ID: 29807766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.